Literature DB >> 29549912

γ-Glutamylcysteine synthetase (γ-GCS) as a target for overcoming chemo- and radio-resistance of human hepatocellular carcinoma cells.

Li-Ching Lin1, Chi-Fen Chen2, Chun-Te Ho3, Jun-Jen Liu4, Tsan-Zon Liu5, Chi-Liang Chern6.   

Abstract

AIMS: This study uncovered that the genetically endowed intracellular glutathione contents (iGSH) regulated by the catalytic subunit of γ‑glutamylcysteine synthetase heavy chain (γ‑GCSh) as a prime target for overcoming both the inherited and stimuli-activated chemo- and radio-resistance of hepatocellular carcinoma (HCC) cells. MAIN
METHODS: Reactive oxygen species (ROS) production and mitochondrial membrane potential (Δψm) were determined by the probe-based flow cytometry. The TUNEL assay was used as an index of radio-sensitivity and the MTT assay was used as an index of chemo-sensitivity against various anti-cancer agents. iGSH and γ‑GCSh activity were measured by HPLC methods. γ‑GCSh-overexpressing GCS30 cell line was established by tetracycline-controlled Tet-OFF gene expression system in SK-Hep-1 cells. KEY
FINDINGS: The relative radio-sensitivities of a panel of five HCC cells were found to be correlated negatively with both the contents of iGSH and their corresponding γ‑GCSh activities with an order of abundance being Hep G2 > Hep 3B > J5 > Mahlavu > SK-Hep-1, respectively. Similarly, the cytotoxicity response patterns of these HCC cells against arsenic trioxide (ATO), a ROS-producing anti-cancer drug, were exactly identical to the order of ranking instigated by the radiotherapy (RT) treatment. Next, γ‑GCSh-overexpressing GCS30 cells were found to possess excellent ability to profoundly mitigate both the drop of Δψm and apoptotic TUNEL-positive cell population engendered by ATO, cisplatin, doxorubicin, and RT treatments. SIGNIFICANCE: Our data unequivocally demonstrate that γ‑GCSh may represent a prime target for overcoming anti-cancer drugs and RT resistance for HCC cells.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemo- and radio-resistance; GCS30 cells; Hepatocellular carcinoma; Intracellular glutathione (iGSH); ROS-producing anti-cancer drugs; γ‑Glutamylcysteine synthetase heavy chain (γ‑GCSh)

Mesh:

Substances:

Year:  2018        PMID: 29549912     DOI: 10.1016/j.lfs.2018.02.015

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  4 in total

1.  Down-regulated lncRNA TP73-AS1 reduces radioresistance in hepatocellular carcinoma via the PTEN/Akt signaling pathway.

Authors:  Wei Song; Jingjing Zhang; Qingxin Xia; Miaomiao Sun
Journal:  Cell Cycle       Date:  2019-09-29       Impact factor: 4.534

Review 2.  Oxidative Stress in Cancer.

Authors:  John D Hayes; Albena T Dinkova-Kostova; Kenneth D Tew
Journal:  Cancer Cell       Date:  2020-07-09       Impact factor: 31.743

3.  The reversal of drug resistance by two-dimensional titanium carbide Ti2 C (2D Ti2C) in non-small-cell lung cancer via the depletion of intracellular antioxidant reserves.

Authors:  Yue Zhu; Baiyan Sui; Xin Liu; Jiao Sun
Journal:  Thorac Cancer       Date:  2021-11-05       Impact factor: 3.500

4.  Tenacissoside H Induces Autophagy and Radiosensitivity of Hepatocellular Carcinoma Cells by PI3K/Akt/mTOR Signaling Pathway.

Authors:  Jiatian Lin; Jiyin Ruan; Hao Zhu; Zaizhong Chen; Junhui Chen; Hongjian Yu
Journal:  Dose Response       Date:  2021-05-13       Impact factor: 2.658

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.